Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
| Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
|---|---|---|---|---|
| Obayashi-Ishii M et al. | 2018 | intact cell/cell culture, HSC-3 cells (human oral squamous cell carcinoma) | static magnetic field | - |
| Gurhan H et al. | 2021 | intact cell/cell culture, HT-1080 (fibrosarcoma cells) | static magnetic field | - |
| Bajtoš M et al. | 2024 | intact cell/cell culture, HT-1080 (fibrosarcoma cells) | static magnetic field, magnetic field, 50/60 Hz, co-exposure | - |
| Castello PR et al. | 2014 | intact cell/cell culture, HT1080 cells (human fibrosarcoma cell line) | RF field, magnetic field, static magnetic field, co-exposure | - |
| Gurhan H et al. | 2018 | intact cell/cell culture, HT1080 cells (human fibrosarcoma cell line) | static magnetic field | - |
| Raylman RR et al. | 1996 | intact cell/cell culture, HTB 63 (melanoma cells), HTB 77 IP3 (ovarian carcinoma cells) and CCL 86 (lymphoma cells) | static magnetic field | 7 T |
| Comfort KK et al. | 2013 | intact cell/cell culture, HaCaT cells (human keratinocytes cell line) | static magnetic field, co-exposure, also other exposures without EMF | - |
| Hiraoka M et al. | 1992 | intact cell/cell culture, HeLa S3 (human cervical carcinoma cell line) | static magnetic field | 0.18–0.2 T |
| Sato K et al. | 1992 | intact cell/cell culture, HeLa S3 (human cervical carcinoma cell line) | static magnetic field | 0.2 T |
| Wang Z et al. | 2014 | intact cell/cell culture, HeLa cell line (human adenocarcinoma cell line) and MCF-7 (human breast cancer cell line) | static magnetic field, DC | 0.26–0.33 T |
| Zafari J et al. | 2015 | intact cell/cell culture, HeLa cell line (human adenocarcinoma cell line) and fibroblasts | static magnetic field, DC | 5–30 mT |
| Schwenzer NF et al. | 2007 | intact cell/cell culture, Hel 299 (human fibroblast cell line) | static magnetic field, magnetic field, MRI | - |
| Song C et al. | 2021 | intact cell/cell culture, IOSE 386 (normal human ovarian cells), SKOV 3 and HO 8910 (ovarian carcinoma cells), animal, mouse/BALB/c (nude mice), whole body | static magnetic field | - |
| Esformes I et al. | 1981 | intact cell/cell culture, JY human lymphocytes, WI-18 human embryonic fibroblasts, LM mouse embryo fibroblast, animal, rat | static magnetic field | 50 mT |
| Ghibelli L et al. | 2006 | intact cell/cell culture, Jurkat cells (human lymphoblastoid T cells) and U937 (human leukemic monocyte cell line) | static magnetic field, MRI, therapeutic/medical device | 6 mT–1 T |
| Aldinucci C et al. | 2003 | intact cell/cell culture, Jurkat cells (human lymphoblastoid T cells) and human lymphocytes | static magnetic field, MRI | 4.75 T |
| Aldinucci C et al. | 2003 | intact cell/cell culture, Jurkat cells (human lymphoblastoid T cells) and human lymphocytes | magnetic field, static magnetic field, low frequency, DC, MRI | 0.7 mT–4.75 T |
| Chen WF et al. | 2010 | intact cell/cell culture, K562 cells (human erythroleukemic cell line) | static magnetic field, co-exposure | 8.8 mT |
| Sun RG et al. | 2012 | intact cell/cell culture, K562 cells (human erythroleukemic cell line) | static magnetic field | 8.8 mT |
| Zhao B et al. | 2021 | intact cell/cell culture, K7M2 (murine osteosarcoma cell line), MG63 (human osteosarcoma cell line), animal, mouse/BALB/c with injected K7M2 osteosarcoma stem cells | static magnetic field | - |
| Butler BC et al. | 1964 | intact cell/cell culture, KB cells | static magnetic field | - |
| Guisasola C et al. | 2002 | intact cell/cell culture, L-132 (human embryonic lung tissue) | RF field, magnetic field, static magnetic field, DC, MRI | 1.5 T |
| Coletti D et al. | 2007 | intact cell/cell culture, L6 cells (rat myogenic cells) | static magnetic field | 80 mT |
| Diatroptova MA et al. | 2022 | intact cell/cell culture, L929 cells (murine fibroblast cells), embryonic fibroblast-like cells of C57BI/6 mice, animal, C57BL/6 mouse | geomagnetic field, also other exposures without EMF, shielding/field deprivation | - |
| Wang Z et al. | 2009 | intact cell/cell culture, LVEC cells (human embryoid body derived cell line) | static magnetic field | - |
| Yang J et al. | 2018 | intact cell/cell culture, MC3T3-E1 cells (mouse osteoblast-like cell line) | static magnetic field, shielding/field deprivation | - |
| Yamaguchi-Sekino S et al. | 2023 | intact cell/cell culture, MC3T3-E1 cells (mouse osteoblast-like cell line) | static magnetic field | - |
| Tang B et al. | 2020 | intact cell/cell culture, MC3T3-E1 cells (mouse osteoblast-like cell line), partly on ZnFe<sub>2</sub>O<sub>4</sub> coatings | static magnetic field, also other exposures without EMF, co-exposure | - |
| Kotani H et al. | 2002 | intact cell/cell culture, MC3T3-E1 cells (mouse osteoblast-like cells), animal, mouse/ddY, whole body | static magnetic field | 8 T |
| Pacini S et al. | 1999 | intact cell/cell culture, MCF-7 (human breast cancer cell line) | static magnetic field, MRI, co-exposure | 200 mT |
| Hajipour Verdom B et al. | 2018 | intact cell/cell culture, MCF-7 (human breast cancer cell line) and HFF cells (human foreskin fibroblast cells) | static magnetic field, DC | - |
| Paun IA et al. | 2018 | intact cell/cell culture, MG-63 (human osteoblast-like cells) | static magnetic field | - |
| Yuan Z et al. | 2018 | intact cell/cell culture, MG-63 (human osteoblast-like cells) and magnetic iron oxide nanoparticles incorprated into 3D collagen model | static magnetic field, co-exposure | - |
| Chiu KH et al. | 2007 | intact cell/cell culture, MG63 (osteoblast-like cells) | static magnetic field | 0.1–0.4 T |
| Yang JC et al. | 2010 | intact cell/cell culture, MG63 (osteoblast-like cells) | static magnetic field | 0.4 T |
| Feng SW et al. | 2010 | intact cell/cell culture, MG63 (osteoblast-like cells) | static magnetic field | 0.4 T |
| Zhang B et al. | 2023 | intact cell/cell culture, MLO-Y4 (osteocyte-like cells) | static magnetic field | - |
| Wang S et al. | 2022 | intact cell/cell culture, MNNG/HOS, U-2 OS and MG63 (human osteosarcoma cell lines) | static magnetic field, co-exposure, also other exposures without EMF | - |
| Feng C et al. | 2022 | intact cell/cell culture, NIH3T3 cells (mouse fibroblast cell line), L929 cells (murine fibroblast cells), animal, mouse/BKS wild-type (WT), BKS-Lepr<sup>db</sup>/J (db/db) and WT | static magnetic field | - |
| Lin CT et al. | 2008 | intact cell/cell culture, NIH3T3 cells (mouse fibroblasts) | static magnetic field, DC | 0.4 T |
| Ledda M et al. | 2013 | intact cell/cell culture, NT2 (human pluripotent embryonal carcinoma cells) | magnetic field, static magnetic field, low frequency | 2.5–10 µT |
| Blackman CF et al. | 1998 | intact cell/cell culture, PC-12 cells (pheochromocytoma cell line from rat adrenal gland) | magnetic field, low frequency, DC, static magnetic field | 23.8–36.6 µT |
| Wang Z et al. | 2010 | intact cell/cell culture, PC-12 cells (pheochromocytoma cell line from rat adrenal gland) | static magnetic field | 0.28 mT |
| Short WO et al. | 1992 | intact cell/cell culture, PS1273 (human malignant melanoma cell line) and DMD-A (human fibroblasts) | static magnetic field, MRI | 500 mT–4.7 T |
| Huyan T et al. | 2020 | intact cell/cell culture, RAW 264.7 (murine pre-osteoclast cells) | static magnetic field | - |
| Gamboa OL et al. | 2007 | intact cell/cell culture, RN 22 (rat Schwann cell line) | static magnetic field | - |
| Mo WC et al. | 2013 | intact cell/cell culture, SH-SY5Y (human neuroblastoma cell line) | geomagnetic field, shielding/field deprivation | 200 nT |
| Calabro E et al. | 2013 | intact cell/cell culture, SH-SY5Y (human neuroblastoma cell line) | static magnetic field | 2.2 mT |
| Medeiros HR et al. | 2023 | intact cell/cell culture, SH-SY5Y (human neuroblastoma cell line) | static magnetic field | - |
| Frachini ECG et al. | 2023 | intact cell/cell culture, SH-SY5Y (human neuroblastoma cell line) | static magnetic field | - |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.
